Die Behandlung androgenisierter Frauen mit intramuskulär applizierbarem Cyproteronacetat

The study evaluated the effectiveness of intramuscular cyproterone acetate (CPA) in treating hyperandrogenism in 42 women, with a total of 293 treatment cycles. Patients received 300 mg of CPA monthly, followed by 40 μg of oral ethinylestradiol for 21 days. The treatment was applied as primary therapy and as a follow-up for those who failed low-dose and high-dose oral CPA therapies. Results showed satisfactory to good responses in hirsutism: 83.5% in primary therapy, 100% in low-dose failures, and 57% in high-dose failures. Seborrhea improved in 100% of primary and low-dose groups and 89% in the high-dose group, while acne and androgenetic alopecia improved in all groups. Side effects were similar to those of high-dose oral CPA, leading to treatment discontinuation in only 3 cases. Although the pharmacokinetics study did not clarify the clinical superiority of parenteral CPA, the findings suggested it was an effective treatment for hirsutism.